Status:
COMPLETED
The Adjunctive Ventricular Arrhythmia Suppression Trial (AVAST) Pilot
Lead Sponsor:
Hartford Hospital
Collaborating Sponsors:
Gilead Sciences
Conditions:
Arrhythmia
Eligibility:
All Genders
Phase:
NA
Brief Summary
The purpose of this study is to learn if combination therapy with amiodarone and ranolazine (an approved drug for chest pain) can help prevent arrhythmias.
Eligibility Criteria
Inclusion
- Patients with an ICD who were on a stable dose of amiodarone for the past 60 days
Exclusion
- Patients with a life expectancy of less than 6 months
- Patients with moderate or severe hepatic impairment (Child-Pugh Classes B or C) or requiring hemodialysis.
- Pregnancy or lactation.
- Treatment with potent CYP3A inhibitors, including ketoconazole, itraconazole, clarithromycin, nefazodone, nelfinavir, indinavir, and saquinavir
- Treatment with CYP3A inducers, including rifampin, rifabutin, rifapentine, phenobarbital, phenytoin, carbamazepine, and St. John's wort.
Key Trial Info
Start Date :
February 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2013
Estimated Enrollment :
19 Patients enrolled
Trial Details
Trial ID
NCT01480336
Start Date
February 1 2011
End Date
January 1 2013
Last Update
March 19 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hartford Hospital
Hartford, Connecticut, United States, 06102